Baclofen is the standard drug of choice for the treatment of spasticity. However, it has a narrow absorption window in the intestine, and after absorption, is rapidly cleared from blood. To offer adequate symptom relief, the drug has to be administered frequently.
Our lead, Sun 09 is a prodrug of Baclofen and being developed as “an efficient Baclofen”. Unlike Baclofen, this NCE would avoid narrow window of absorption, enabling the absorbtion throughout the length of the intestine, thus offering better systemic availability from an equivalent dose.
In extensive animal studies Sun 09 had shown good efficacy without any additional safety concerns.
Phase I studies have now been completed satisfactorily with the IR tablet, where good absorption and no dose limiting toxicity was observed., Phase I studies of the slow release formulation of SUN-09 is under way.